Overview
Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy
Status:
Completed
Completed
Trial end date:
2000-07-01
2000-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this trial is to determine the maximum tolerated dose and the toxicities of paclitaxel given as a short hour infusion in children with refractory malignancy.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
National Cancer Institute (NCI)Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Criteria
DISEASE CHARACTERISTICS:Histologically confirmed cancer (including leukemia) that is: Refractory to standard
therapy (objective disease progression required) OR For which no standard therapy exists
and patient is ineligible for potentially curative surgery.
PRIOR/CONCURRENT THERAPY:
Recovery from the toxic effects of prior therapy required.
Biologic Therapy: Not specified.
Chemotherapy: No prior taxanes. At least 3 weeks since myelosuppressive therapy (6 weeks
since nitrosourea).
Endocrine Therapy: Not specified.
Radiotherapy: Prior extensive craniospinal or pelvic irradiation allowed.
Surgery: Ineligible for potential curative surgery.
Other: Prior bone marrow transplant allowed.
PATIENT CHARACTERISTICS:
Age: Over 1 to 21;
Performance status: ECOG 0-2;
Life expectancy: At least 8 weeks.
Hematopoietic: (except with leukemia, bone marrow involvement, history of bone marrow
transplantation, or extensive prior radiotherapy).
Absolute granulocyte count at least 1,500/mm(3);
Platelet count at least 100,000/mm(3);
Hemoglobin at least 8.0 g/dL.
Hepatic:
Bilirubin no greater than 1.5 mg/dL;
AST less than 2 times normal.
Renal:
Creatinine no greater than 1.5 mg/dL OR;
Creatinine clearance at least 60 mL/min per square meter.
OTHER:
No concurrent anticonvulsant therapy.
No grade 2 or worse neuropathy.
No significant systemic illness (e.g., infection) that could compromise drug excretion or
confuse assessment of toxicity.
Not pregnant or nursing.